| Symbol | FATE |
|---|---|
| Name | FATE THERAPEUTICS INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biological Products, (No Diagnostic Substances) |
| Address | 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA 92131 |
| Telephone | 858.875.1803 |
| Fax | — |
| — | |
| Website | https://www.fatetherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001434316 |
| Description | Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The companys cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients. Additional info from NASDAQ: |
TAHL CINDY 🟡 adjusted position in 0 shares (2 derivative) of FATE THERAPEUTICS INC (FATE) at $1.32 Transaction Date: May 06, 2026 | Filing ID: 211820
Read moreEPSTEIN ROBERT S 🟢 acquired 50.0K shares (1 derivative) of FATE THERAPEUTICS INC (FATE) at $1.69 Transaction Date: May 05, 2026 | Filing ID: 208899
Read moreRASTETTER WILLIAM H 🟢 acquired 50.0K shares (1 derivative) of FATE THERAPEUTICS INC (FATE) at $1.69 Transaction Date: May 05, 2026 | Filing ID: 208891
Read moreFate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Read moreFate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting
Read moreNew Form ARS - FATE THERAPEUTICS INC <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001193125-26-177241 <b>Size:</b> 4 MB
Read moreNew Form DEFA14A - FATE THERAPEUTICS INC <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001193125-26-177171 <b>Size:</b> 135 KB
Read moreNew Form DEF 14A - FATE THERAPEUTICS INC <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001193125-26-177094 <b>Size:</b> 2 MB
Read moreNew Form SCHEDULE 13D/A - FATE THERAPEUTICS INC <b>Filed:</b> 2026-04-22 <b>AccNo:</b> 0001104659-26-047066 <b>Size:</b> 28 KB
Read moreFate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences
Read more